<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[OncoSec Medical Incorporated 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=34158></link><description><![CDATA[OncoSec Medical Incorporated 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Mon, 04 May 2026 07:20:14 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2019/12/12_3554238800_20191203101127_5759087342.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[OncoSec Announces Closing of the CGP/Sirtex Transaction]]></title><link>https://www.newswire.co.kr/newsRead.php?no=901068</link><description><![CDATA[SAN DIEGO & PENNINGTON, N.J.--(Business Wire/Korea Newswire)--OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today announced that, following shareholder approval, the proposed strategic investment by and partnership (the “CGP/Sirtex Transaction”) with Grand Decade Developments Limited, a wholly owned subsidiary o...]]></description><pubDate>Tue, 11 Feb 2020 09:58:22 +0900</pubDate></item><item><title><![CDATA[온코섹, CGP/설텍스 거래에 대한 주주 승인 획득]]></title><link>https://www.newswire.co.kr/newsRead.php?no=901029</link><description><![CDATA[샌디에이고/페닝턴, 뉴저지--(Business Wire/뉴스와이어)--후기 단계의 종양 내 암 면역요법을 개발하고 있는 온코섹 메디컬(OncoSec Medical Incorporated)(나스닥: ONCS)(이하 ‘회사’ 또는 ‘온코섹’)의 특별 주주총회에서 차이나 그랜드 파마슈티컬 앤 헬스케어 홀딩스(China Grand Pharmaceutical and Healthcare Holdings Limited, 이하 CGP)의 완전 자회사인 그랜드 디케이드 디벨로프먼트(Grand Decade Developments Limited)...]]></description><pubDate>Mon, 10 Feb 2020 12:57:53 +0900</pubDate></item><item><title><![CDATA[OncoSec Announces that Shareholders Have Approved CGP/Sirtex Transaction]]></title><link>https://www.newswire.co.kr/newsRead.php?no=901028</link><description><![CDATA[SAN DIEGO & PENNINGTON, N.J.--(Business Wire/Korea Newswire)--OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today announced that, at its Special Meeting of Shareholders (the “Special Meeting”), based on a preliminary vote count provided by the Company’s proxy solicitor, OncoSec shareholders have approved the pro...]]></description><pubDate>Mon, 10 Feb 2020 12:57:18 +0900</pubDate></item><item><title><![CDATA[OncoSec Announces that Nevada Court Denies Alpha Holdings’ Motion to Enjoin Special Meeting of Shareholders]]></title><link>https://www.newswire.co.kr/newsRead.php?no=901023</link><description><![CDATA[SAN DIEGO & PENNINGTON, N.J.--(Business Wire/Korea Newswire)--OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today commented on the February 6 ruling from the District Court in Clark County, Nevada, denying Alpha Holdings, Inc.’s (“Alpha”) motion to enjoin OncoSec’s Special Meeting of Shareholders (the “Special M...]]></description><pubDate>Mon, 10 Feb 2020 11:40:46 +0900</pubDate></item><item><title><![CDATA[온코섹 발표: 네바다 법원, 알파 홀딩스의 주주 특별총회 개최 금지 신청 기각]]></title><link>https://www.newswire.co.kr/newsRead.php?no=901025</link><description><![CDATA[샌디에이고/페닝턴, 뉴저지--(Business Wire/뉴스와이어)--후기 단계 종양내 면역요법을 개발하고 있는 온코섹 메디컬(OncoSec Medical Incorporated)(나스닥: ONCS)(이하 ‘회사’ 또는 ‘온코섹’)이 차이나 그랜드 파마슈티컬 앤 헬스케어 홀딩스(China Grand Pharmaceutical and Healthcare Holdings Limited)의 완전 자회사인 그랜드 디케이드 디벨로프먼트(Grand Decade Developments Limited)와 미국 계열사인 설텍스 메디컬 US ...]]></description><pubDate>Mon, 10 Feb 2020 11:38:49 +0900</pubDate></item><item><title><![CDATA[OncoSec Urges Shareholders to Focus on the Critical Benefits of CGP/Sirtex Transaction]]></title><link>https://www.newswire.co.kr/newsRead.php?no=900668</link><description><![CDATA[SAN DIEGO & PENNINGTON, N.J.--(Business Wire/Korea Newswire)--OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today issued the following statement to its shareholders related to the upcoming Special Meeting to vote on the proposed strategic investment by and partnership (the “CGP/Sirtex Transaction”) with Grand De...]]></description><pubDate>Mon, 03 Feb 2020 08:55:09 +0900</pubDate></item><item><title><![CDATA[OncoSec Urges Shareholders Not to Fall for Alpha’s Disingenuous “Proposal” and Scheme to Prevent Fair Vote at Special Meeting]]></title><link>https://www.newswire.co.kr/newsRead.php?no=900526</link><description><![CDATA[SAN DIEGO & PENNINGTON, N.J.--(Business Wire/Korea Newswire)--OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today issued the following statement to its shareholders regarding Alpha Holdings, Inc.’s (“Alpha”) January 27, 2020 press release:  · Alpha’s press release about a “revised binding term sheet” provided to...]]></description><pubDate>Wed, 29 Jan 2020 09:22:23 +0900</pubDate></item><item><title><![CDATA[OncoSec Sends Letter Urging Shareholders Not to Be Distracted by Alpha’s Last-Ditch Efforts to Derail CGP/Sirtex Transaction]]></title><link>https://www.newswire.co.kr/newsRead.php?no=900347</link><description><![CDATA[SAN DIEGO & PENNINGTON, N.J.--(Business Wire/Korea Newswire)--Daniel O’Connor, President, Director &amp; CEO of OncoSec Medical Incorporated (NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today sent the following letter to shareholders. The full text of the letter and additional information can be found at   January 21, 2020  Dear Valued OncoSec Shareholder,  I recogniz...]]></description><pubDate>Wed, 22 Jan 2020 09:42:01 +0900</pubDate></item><item><title><![CDATA[OncoSec Board Rejects Alpha Holdings “Proposal” and Announces New Special Meeting Date]]></title><link>https://www.newswire.co.kr/newsRead.php?no=900158</link><description><![CDATA[SAN DIEGO & PENNINGTON, N.J.--(Business Wire/Korea Newswire)--OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today announced that its Board of Directors (the “Board”) has determined the Alpha Holdings, Inc. (“Alpha”) proposal conveying a preliminary financing offer is not in the best interests of all shareholder...]]></description><pubDate>Fri, 17 Jan 2020 08:44:48 +0900</pubDate></item><item><title><![CDATA[OncoSec Sends Letter to Shareholders Highlighting that Both Leading Independent Proxy Advisory Firms - ISS and Glass Lewis - Have Recommended That OncoSec Shareholders Vote “FOR” the CGP/Sirtex Transaction on the WHITE Proxy Card]]></title><link>https://www.newswire.co.kr/newsRead.php?no=899714</link><description><![CDATA[SAN DIEGO & PENNINGTON, N.J.--(Business Wire/Korea Newswire)--OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today issued the following letter to its shareholders. The full text of the letter and additional information can be found at   January 6, 2020  Dear Valued OncoSec Shareholder,  As you are likely aware, ...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2020/01/3554238800_20200107101845_9830087197.jpg]]></url></image><pubDate>Tue, 07 Jan 2020 10:30:25 +0900</pubDate></item><item><title><![CDATA[Institutional Shareholder Services Inc. (“ISS”) Recommends OncoSec Shareholders Vote “FOR” the CGP/Sirtex Transaction]]></title><link>https://www.newswire.co.kr/newsRead.php?no=899391</link><description><![CDATA[SAN DIEGO & PENNINGTON, N.J.--(Business Wire/Korea Newswire)--OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today announced that Institutional Shareholder Services Inc. (“ISS”), a leading proxy advisory firm that provides objective and independent analysis and voting recommendations for contested situations, ha...]]></description><pubDate>Fri, 27 Dec 2019 09:41:18 +0900</pubDate></item><item><title><![CDATA[OncoSec Responds to Alpha’s “Proposal”]]></title><link>https://www.newswire.co.kr/newsRead.php?no=899256</link><description><![CDATA[SAN DIEGO & PENNINGTON, N.J.--(Business Wire/Korea Newswire)--OncoSec Medical Incorporated (NASDAQ:ONCS), (the “Company” or “OncoSec”) today issued the following response to the latest press release from Alpha Holdings, Inc. (Alpha):  “Throughout its campaign to stop OncoSec’s proposed strategic transaction (the “CGP/Sirtex Transaction”) with Grand Decade Developments Limited, a wholly owned subsidiary of ...]]></description><pubDate>Mon, 23 Dec 2019 11:00:56 +0900</pubDate></item><item><title><![CDATA[OncoSec Releases Presentation Spotlighting the Benefits of the Proposed CGP/Sirtex Transaction and Partnership]]></title><link>https://www.newswire.co.kr/newsRead.php?no=899247</link><description><![CDATA[SAN DIEGO & PENNINGTON, N.J.--(Business Wire/Korea Newswire)--OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today announced the release of a detailed presentation highlighting the Company’s strategic rationale - and benefits for shareholders - of the proposed transaction with Grand Decade Developments Limited, ...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2019/12/3554238800_20191223102208_8559580191.jpg]]></url></image><pubDate>Mon, 23 Dec 2019 10:28:54 +0900</pubDate></item><item><title><![CDATA[OncoSec CEO Sends Letter to Fellow Shareholders]]></title><link>https://www.newswire.co.kr/newsRead.php?no=898824</link><description><![CDATA[SAN DIEGO & PENNINGTON, N.J.--(Business Wire/Korea Newswire)--Daniel O’Connor, President, Director &amp; CEO of OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today sent the following letter to shareholders. The full text of the letter and additional information can be found at   December 12, 2019  Dear Fellow On...]]></description><pubDate>Fri, 13 Dec 2019 13:47:49 +0900</pubDate></item><item><title><![CDATA[온코섹, CGP/설텍스 전략적 투자 설명 동영상 배포… 주주 이익 창출 이유 강조]]></title><link>https://www.newswire.co.kr/newsRead.php?no=898610</link><description><![CDATA[샌디에이고/페닝턴, 뉴저지--(Business Wire/뉴스와이어)--후기 종양 내 암 면역요법 개발사인 온코섹 메디컬 인코퍼레이티드(OncoSec Medical Incorporated, 이하 회사 또는 온코섹)(나스닥: ONCS)가 그랜드 파마슈티컬 앤 헬스케어 홀딩스 리미티드(China Grand Pharmaceutical and Healthcare Holdings Limited, 이하 CGP)의 완전 자회사인 그랜드 디케이드 디벨로프먼트 리미티드(Grand Decade Developments Limited)와 CGP의 미...]]></description><pubDate>Tue, 10 Dec 2019 11:48:11 +0900</pubDate></item><item><title><![CDATA[OncoSec Releases Video Highlighting Why CGP/Sirtex Strategic Transaction Will Create Significant Shareholder Value]]></title><link>https://www.newswire.co.kr/newsRead.php?no=898609</link><description><![CDATA[SAN DIEGO & PENNINGTON, N.J.--(Business Wire/Korea Newswire)--OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, released a video featuring its President and Chief Executive Officer, Daniel J. O’Connor, discussing why shareholders should vote in favor of the proposed strategic transaction with Grand Decade Developme...]]></description><pubDate>Tue, 10 Dec 2019 11:45:50 +0900</pubDate></item><item><title><![CDATA[온코섹, 알파홀딩스 제출 개정 예비 위임장 설명서의 문제 소지에 대한 입장 표명]]></title><link>https://www.newswire.co.kr/newsRead.php?no=898455</link><description><![CDATA[샌디에이고/페닝턴, 뉴저지--(Business Wire/뉴스와이어)--온코섹 메디컬 인코퍼레이티드(OncoSec Medical Incorporated)(나스닥: ONCS)(이하 회사 또는 온코섹)가 2019년 12월 3일 알파홀딩스(Alpha Holdings, 이하 알파)가 제출한 개정 예비 위임장 설명서 내 문제의 소지가 있는 투표 계획에 대한 입장문을 발표했다.   해당 내용은 아래와 같다.   거래 제안을 명백히 무효화할 수준으로 특별 주주총회에 올려진 안건에 대한 반...]]></description><pubDate>Fri, 06 Dec 2019 11:12:35 +0900</pubDate></item><item><title><![CDATA[OncoSec Comments on Disturbing Elements of Alpha Holdings’ Revised Preliminary Proxy Filing]]></title><link>https://www.newswire.co.kr/newsRead.php?no=898454</link><description><![CDATA[SAN DIEGO & PENNINGTON, N.J.--(Business Wire/Korea Newswire)--OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, issued a statement highlighting a troubling voting scheme buried in Alpha Holdings, Inc.’s (“Alpha”) revised preliminary proxy statement filed on December 3, 2019.  The relevant section is below:  If we o...]]></description><pubDate>Fri, 06 Dec 2019 11:06:52 +0900</pubDate></item><item><title><![CDATA[OncoSec Sets the Record Straight on Alpha Holdings’ False and Misleading Statements]]></title><link>https://www.newswire.co.kr/newsRead.php?no=898260</link><description><![CDATA[SAN DIEGO & PENNINGTON, N.J.--(Business Wire/Korea Newswire)--OncoSec Medical Incorporated (NASDAQ: ONCS), (the “Company” or “OncoSec”) a company developing late-stage intratumoral cancer immunotherapies, today issued the following letter to shareholders. The full text of the letter and additional information can be found at   December 2, 2019  Dear Fellow OncoSec Shareholders,  OncoSec Medical Incorporate...]]></description><pubDate>Tue, 03 Dec 2019 10:24:30 +0900</pubDate></item></channel></rss>